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paradigm?
ABSTrACT
Vitamin B12 supplementation in specific clinical condi-
tions in diabetic patients has been recommended in the 
guidelines. These recommendations reflect reports con-
firming the importance of vitamin B12 supplementation 
in the treatment of diabetic complications, as well as 
to correct its deficiency during metformin treatment. 
In the present article, we reviewed the issue of vita-
min B12 deficiency, the relevant diagnostic approach, 
and the rationale for vitamin B12 supplementation in 
diabetic patients. (Clin Diabetol 2020; 9; 6: 489–496)
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Do we know how important is vitamin 
B12 in humans?
Vitamin B12 is absorbed in the terminal part of the 
ileum. A prerequisite for this process is the presence 
of a glycoprotein known as the intrinsic factor which 
is produced by the parietal cells of the stomach. When 
bound to the intrinsic factor, cobalamin forms a hemat-
opoietic factor which plays a role in cell formation in 
the hematopoietic system. In addition, it is a necessary 
factor for erythropoiesis in bone marrow and DNA 
and RNA synthesis in erythroblasts. Vitamin B12 is also 
involved in purine and pyrimidine metabolism [1, 2]. 
The effects of vitamin B12 or cobalamin on the hu-
man body are complex. It is directly involved in the conver-
sion of methylmalonyl-coenzyme A to succinyl-coenzyme 
A (Fig. 1). This reaction creates a substrate for the Krebs 
cycle, thus providing energy for multiple processes in the 
human body. Body systems that particularly actively use 
this process include the nervous, gastrointestinal, immu-
nologic, and hematopoietic systems [3, 4].
Methionine synthesis is another biochemical pro-
cess vitamin B12 is a cofactor of (Fig. 2). An adequate 
rate of this process is necessary for myelinization 
(formation of nerve sheaths) which is necessary for 
maintaining appropriate nerve conduction. In addition, 
there is an association between methionine synthesis 
and synthesis of some neurotransmitters (dopamine, 
noradrenaline, and serotonin) [4, 5]. 





















Figure 2. Methionin synthesis
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Due to vitamin B12 involvement in the above men-
tioned processes, its deficiency may have various clinical 
manifestations (Table 1) [1, 2].
What are the primary sources  
of vitamin B12?
The process of cobalamin absorption from the food 
and its utilization in the body is complex and thus may 
be adversely affected by multiple clinical conditions.
One of the most important determinants of vitamin 
B12 level is its dietary intake. The average vitamin B12 
dietary content is 3–30 µg, and the daily requirement 
is only 0.6–1.2 µg. Patients on a diet poor in cobalamin 
sources (meat, milk, eggs, cheese, fish) are at particular 
risk of cobalamin deficiency. Body cobalamin stores 
are large enough to make a deficiency exclusively due 
to poor dietary intake unlikely, unless an individual is 
on a restrictive vegetarian or vegan diet. As the latter 
dietary choices are increasingly popular, this risk should 
be recognized and patients should be reminded of a 
potential need for cobalamin supplementation [6].
Vitamin B12 deficiency may be due to gastrointes-
tinal disease. Cobalamin absorption in the gastrointes-
tinal tract depends on the presence of several factors 
that protect the cobalamin moiety and transport it to 
the target tissues. These include haptocorrin (produced 
by the salivary glands), intrinsic factor (produced by the 
gastric parietal cells) and transcobalamin II (present in 
the ileum where cobalamin is ultimately absorbed to 
bloodstream). Gastrointestinal pathologies may result 
in reduced levels of these protective factors, leading 
to impaired cobalamin absorption and reduction of 
its serum level [7, 8].
Diseases commonly perceived as inducing vitamin 
B12 deficiency include inflammatory bowel disease 
(ulcerative colitis and Crohn’s disease) and pernicious 
(Addison-Biermer) anaemia. However, diseases less 
frequently associated with vitamin B12 deficiency, such 
as celiac disease, chronic pancreatitis and liver disease, 
may also become major reasons for the need for vitamin 
B12 supplementation [9–11]. Several mechanisms lead-
ing to vitamin B12 deficiency may operate in chronic 
alcohol abuse, including chronic gastric and duodenal 
mucosal inflammation, chronic pancreatitis, and cirrho-
sis. Finally, small intestine bacterial overgrowth (SIBO) 
may predispose to impaired absorption of micro- and 
macronutrients, and another potential cause is the 
presence of gastrointestinal parasites [3, 4, 12]. 
Impaired absorption may also have iatrogenic 
causes, in particular in patients after resection proce-
dures involving those gastrointestinal tract segments 
which are responsible for vitamin B12 absorption, in 
particular the stomach and the ileum. In the present 
era of growing popularity of bariatric surgery, it is par-
ticularly important to monitor vitamin B12 deficiencies 
and provide adequate supplementation in this patient 
group [13]. 
Medications may be a common cause for impaired 
vitamin B12 absorption. These include metformin, pro-
ton pump inhibitors, H2 receptor blockers, antibiotics, 
anticonvulsants, calcium antagonists, and 5-amino-
salicylates [14–16]. Paradoxically, the latter stabilize 
inflammation in inflammatory bowel diseases but may 
themselves predispose to cobalamin deficiency [17].
What are the causes of vitamin B12  
deficiency in diabetes?
Diabetic patients are particularly prone to vita-
min B12 deficiency. The causes of the latter may be 
somewhat different in patients with type 1 and type 2 
diabetes.
In type 1 diabetes, this is mostly associated with 
an increased risk of concomitant autoimmune disease, 
such as autoimmune thyroiditis. Individuals with hy-
pothyroidism were shown to have macrocytosis, and 
often also resultant macrocytic anaemia [18]. It may be 
a sign of thyroid disease or result from a concomitant 
autoimmune disease limiting cobalamine absorption. 
Celiac disease and Addison-Biermer anaemia are also 
more common in patients with type 1 diabetes [19, 
20]. A typical feature of long-standing poorly controlled 
type 1 diabetes are microangiopathic complications 
which may result in autonomic neuropathy involving 
the gastrointestinal system, manifesting with gastro-
paresis and enteropathy [21].
Patients with type 2 diabetes more often present 
with macroangiopathic complications resulting in 
potentially more diffuse perfusion abnormalities [22]. 
Table 1. Effects of vitamin B12 deficiency











Gastrointestinal system Gastrointestinal mucosal atrophy
Stomatitis
Change in bowel movement pattern
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One such manifestation may be atherosclerotic mesen-
teric artery disease, potentially leading to significantly 
impaired intestinal absorption due to ischemia, or 
even intestinal necrosis with more severe ischemic 
events such as mesenteric artery embolism. Patients 
with type 2 diabetes are also at a higher risk of inflam-
matory conditions, resulting in more frequent use of 
antibiotics [23]. In addition, bariatric procedures are 
often performed in these patients due to concomitant 
obesity, depriving them of a large intestinal surface to 
absorb vitamin B12 [13]. Diabetic patients are often 
subjected to various dietary interventions. If these are 
misunderstood or overly restrictive, they may lead to an 
unbalanced diet with potential deficiencies of multiple 
micro- and macronutrients.
The effect of medications on cobalamin absorption 
seems more important in diabetic patients compared 
to those without diabetes. In addition to metformin, 
which has been frequently highlighted in this regard 
in the recent literature, these patients are more com-
monly treated with calcium antagonists, proton pump 
inhibitors, and acetylsalicylic acid [14, 15, 24].
Apart from these typical predispositions, it should 
be always borne in mind during the diagnostic process 
that vitamin B12 deficiency in a diabetic patient may re-
sult from clinical conditions independent from diabetes. 
What may be the consequences  
of long-standing vitamin B12 deficiency  
in a diabetic patient?
Vitamin B12 deficiency in a diabetic patient may 
potentially affect both micro- and macroangiopathic 
changes.
Neuropathy is of major importance among the 
microangiopathic complications, and it may result from 
vitamin B12 deficiency even without concomitant dia-
betes. Among various types of neuropathy, thick motor 
fibres are most sensitive to vitamin B12 deficiency, which 
may manifest with loss of balance or foot deformi-
ties. In a diabetic patient, it is difficult to ascertain the 
primary cause: whether it is uncontrolled diabetes, its 
long duration, unidentified genetic factors, or vitamin 
B deficiencies [25]. However, it seems logical that in a 
patient with diabetic neuropathy, an additional con-
tributing factor may be present. It was shown that co-
balamine deficiency accompanying diabetes promotes 
peripheral neuropathy due to impaired nerve myeliniza-
tion and may alter its clinical presentation, rendering 
it more atypical. Other common causes of neuropathy 
that may coexist with diabetes include alcohol abuse 
(also via cobalamin-independent mechanisms), use of 
neurotoxic drugs, and advanced chronic kidney disease 
(mediated by uremic toxins) [25].
It was initially thought that the major consequence 
of cobalamin deficiency is damage to thick nerve fibres 
but a number of recent studies showed an association 
between vitamin B12 deficiency and various components 
of autonomic nervous system damage. In particular, 
multiple studies focused on the association between 
cobalamin deficiency and cardiovascular autonomic 
dysfunction, including orthostatic hypotension. Hansen 
et al. [26] showed that vitamin B12 deficiency was asso-
ciated with cardiovascular autonomic dysfunction in pa-
tients with type 2 diabetes. Beitzke et al. [27] suggested 
that orthostatic hypotension in diabetic patients may be 
caused by vitamin B12 deficiency, warranting investiga-
tion for the latter. Similar associations were reported 
for autonomic neuropathy involving the gastrointes-
tinal system (gastroparesis, enteropathy, sialorrhoea), 
the genitourinary system (neurogenic bladder, erectile 
dysfunction), and thermoregulation mechanisms (ex-
cessive sweating). However, no evidence is available 
for a direct causal role of vitamin B12 deficiency in the 
development of autonomic neuropathy [28].
Another complication of diabetes is diabetic 
retinopathy. However, some fundoscopy findings are 
not specific for diabetic retinopathy. In their study, 
Satyanayarana et al. [29] suggested that vitamin B12 
deficiency may be an independent risk factor for the 
development of diabetic retinopathy. Retinal bleeding 
identified by ophthalmoscopy may accompany severe 
anaemia or thrombocytopenia, including due to vitamin 
B12 deficiency. These case reports highlighted the role 
of hypoxia as a factor that damages the endothelium. 
Abnormal repair and homeostatic processes are also 
operating. Retinal lesions seem more frequent in pa-
tients with thrombocytopenia accompanying anaemia 
due to vitamin B12 deficiency [30, 31].
In addition to typical retinal pathology, cobalamin 
deficiency may also result in bilateral optic nerve neu-
ropathy. Clinically, it manifests mostly with centrocecal 
scotoma and slowly developing optic nerve atrophy. 
The mechanism of this pathology remains unknown 
but it seems to be related to the role of vitamin B12 as 
a potent free radical scavenger. Chan et al. [32] found 
that the antioxidant effect of cobalamin was a protec-
tive factor for the optic nerve. These authors showed in 
vitro and in an animal model that intravitreal cobalamin 
administration following iatrogenic optic nerve dam-
age reduced oxidative stress and the degree of nerve 
damage, promoting survival of retinal ganglion cells.
Links between vitamin B12 deficiencies and the 
development of macroangiopathy have been sought 
for a long time. Such a link may be related to the 
discussion on the role of homocysteine, particularly 
in the development of coronary artery disease. Until 
Clinical Diabetology 2020, Vol. 9, No 6
492
recently, homocysteine level measurement was rec-
ommended as a cardiovascular risk marker [33, 34]. 
However, these hopes were not substantiated in later 
studies. In contrast, Yigit et al. [35] showed a poten-
tial association between a MTHFR gene mutation and 
the presence of diabetic peripheral neuropathy. The 
genotype distribution and allele frequencies differed 
significantly between patients with diabetic neuropathy 
and the control group and correlated with a history of 
diabetic retinopathy. It was hypothesized that both 
direct and indirect effects of hyperhomocysteinaemia 
on endothelial cells led to occlusion of small capillaries 
which would explain the effect of vitamin B12 deficiency 
on the development of neuropathy.
Does chronic metformin use lead  
to vitamin B12 deficiencies?
In the recent years, numerous reports have indi-
cated that metformin, particularly if used for many 
years, significantly affects body vitamin B12 stores. It 
was shown in diabetic patients treated with metformin, 
women with polycystic ovary syndrome receiving met-
formin treatment, and in healthy women administered 
metformin in trials evaluating its anticancer effects 
[36–38]. In 1971, Tomkin et al. [39] were the first 
to note an association between metformin use and 
reduced vitamin B12 absorption. Randomized clinical 
trials showed that metformin administration for several 
months may significantly reduce vitamin B12 level [36, 
40]. One of the strongest evidence for this association 
comes from a randomized clinical trial with more than 
4 years of follow-up, reported by De Jager et al. [41]. 
This study showed that vitamin B12 level was reduced 
by as much as 19%. It was the first study to show 
gradual vitamin B12 level reduction in patients receiv-
ing metformin, and the first to show the potential of 
metformin to reduce vitamin B12 level to values that 
usually require pharmacological substitution. The rela-
tion reported by De Jager et al. has been supported by 
more recent metaanalyses and clinical studies [42, 43].
Several theories have been put forward to ex-
plain metformin-induced vitamin B12 deficiency. One 
of the earliest proposed explanations was intestinal 
bacterial overgrowth resulting in binding the intrinsic 
factor-vitamin B12 complex by the bacteria instead of 
its absorption [44]. Another postulated mechanism 
was acceleration of intestinal passage by metformin, 
resulting in reduced vitamin absorption [45]. Accord-
ing to the currently most popular explanation, met-
formin affects calcium channels in the small intestine 
which are responsible for absorption of the intrinsic 
factor-vitamin B12 complex [24]. This mechanism is 
also supported by reversal of defective vitamin B12 
absorption by oral calcium supplementation. In their 
study, Bauman et al. [24] divided patients with type 2 
diabetes into two groups, one receiving metformin and 
the other receiving a sulphonylurea. In the metformin 
group, a significant reduction in vitamin B12 and hol-
otranscobalamin level was noted in the first 3 months 
but such effects were not observed in the sulphonylurea 
group. At the next step, oral calcium supplementation 
was initiated in patients receiving metformin. At one 
month, holotranscobalamin level in the study group 
increased by as much as 53%, and no intestinal bacterial 
overgrowth was confirmed [24]. The authors suggested 
that positively charged metformin moieties target the 
carbohydrate core of intestinal cell membrane, charg-
ing positively the membrane surface itself, and calcium 
cations are repelled from it as a result.
Does metformin induce neuropathy?
Should we afraid metformin due to vitamin B12 
deficiencies developing during metformin therapy? It 
has been a leading anti-diabetic drug for decades, pro-
viding multidirectional benefits. Normalization of blood 
glucose levels associated with long-term improvement 
of insulin sensitivity protects from the development of 
diabetic neuropathy. Specific molecular mechanisms of 
the neuroprotective action of metformin independent 
from blood glucose control have also been investigated.
On the other hand, development of various forms 
of diabetes-independent neuropathy due to vitamin 
B12 deficiency may be expected in patients treated 
with metformin for many years [46]. In a 6-month 
observational study, Wile and Toth [47] showed a 
significant effect of metformin use on a reduction 
of cobalamin level, which was also associated with 
elevated homocysteine and methylmalonic acid levels. 
In addition, the severity of peripheral neuropathy was 
increased compared to the non-metformin treated 
group. Singh et al. [48] also showed an association 
between metformin use, vitamin B12 deficiency, and the 
presence of neuropathy. In contrast, Alharbi et al. [49] 
did not show a significantly higher rate of neuropathy 
in metformin-treated patients [49]. Older studies also 
did show a significant association between vitamin B12 
deficiency and peripheral neuropathy in metformin-
treated patients [50]. 
These apparently discrepant results may result 
from difficulties with matching the study groups being 
compared. In observational studies, yielding similar 
study groups for a comparison is probably impossible 
to achieve, as comparisons are only performed between 
metformin-treated versus non-patients, without taking 
into account other factors inducing neuropathy, which 
limits the credibility of the study findings. Future studies 
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with adequate sample sizes and use of more objective 
tools to evaluate peripheral neuropathy are needed to 
evaluate the relationship between metformin use and 
development of peripheral neuropathy in patients with 
type 2 diabetes [51].
Do other anti-diabetic drugs induce  
cobalamin deficiency?
A question arises whether other anti-diabetic drugs 
which also affect the gastrointestinal system function 
may potentially affect vitamin B12 absorption. These 
include glucagon-like peptide-1 (GLP1) analogues. 
dipeptidyl peptidase-4 (DDP-4) inhibitors, and alpha-
glucosidase inhibitors. 
A 2018 study in an animal model showed that ad-
ministering a conjugate of GLP1 analogue and vitamin 
B12 improved blood glucose control and limited adverse 
effects associated with the use of GLP1 analogues 
(vomiting, nausea, fatigue). However, no evidence was 
provided that use of GLP1 analogues would lead to a 
reduction of vitamin B12 level [52] No data are available 
in the literature regarding the effect of DPP-4 inhibitors 
and alpha-glucosidase inhibitors on vitamin B12 levels.
should vitamin B12 level be measured, 
particularly with the presence of other 
factors predisposing to its deficiency?
Most guidelines recommend monitoring vitamin 
B12 levels if risk factors for its deficiency are present, 
and the most recent diabetes management guidelines 
are consistent with this recommendation. The American 
Diabetes Association (ADA) suggests periodic cobala-
min level measurements in patients receiving chronic 
metformin treatment, but without suggesting specific 
time intervals for this testing. ADA also recommended 
targeting individuals with concomitant neuropathy 
and anaemia [53]. In the most recent Diabetes Poland 
guidelines, correction of vitamin B12 deficiency follow-
ing its laboratory confirmation was recommended [29].
How reliable are blood vitamin B12  
level measurements?
In the routine clinical practice, vitamin B12 levels 
are measured either to determine the cause of mac-
rocytic anaemia or due to the presence of clinical 
manifestations suggesting vitamin B12 deficiency. It has 
been questioned in the literature, however, whether 
plasma cobalamin levels reflect its clinical effects. 
Measuring serum cobalamin levels only does not allow 
an adequate insight into its total body stores, as the 
metabolic processes that use cobalamin as a cofactor 
occur at the intracellular level (Figs 1, 2). In addition, the 
effectiveness of these processes may be evaluated only 
indirectly, based on plasma levels of transcobalamin, 
homocysteine, methylmalonic acid (MMA), S-aden-
osylmethionine (SAM), and S-adenosylhomocysteine 
(SAH). It seems that vitamin B12 deficiency should be 
considered at two levels: actual (identified by laboratory 
test) and functional. The latter would be characterized 
by normal serum vitamin B12 levels in the setting of 
its abnormal intracellular distribution, as reflected by 
abnormal levels of the above metabolites, the measure-
ments of which are rarely available commercially [3, 54].
Obeid et al. [55] evaluated these relationships in 
patients with type 2 diabetes and a healthy control 
group. This study measured vitamin B12 and its markers 
including red blood cell-vitamin B12 (B12-RBC), MMA, 
total transcobalamin (tTC), total homocysteine (tHcy) 
and methylation markers SAM and SAH. Cobalamin and 
transcobalamin levels in diabetic patients were similar 
to those in the healthy control group, while MMA level 
was higher, and B12-RBC, SAM, and SAH levels were 
lower. These findings suggest that despite cobalamin 
levels within the laboratory reference range, its cellular 
distribution is disturbed. A reverse trend was observed 
in patients receiving metformin therapy, in whom 
cobalamin levels were lower compared to the control 
group. On the other hand, lower MMA levels and 
normal methylation index suggest normal cobalamin-
dependent intracellular processes in these patients. 
Based on their findings, the authors postulated cellular 
resistance to vitamin B12 in type 2 diabetes [55]. These 
results also indicate that interpretation of cobalamin 
level measurements should be cautious, and measuring 
other parameters listed above might be helpful.
should cobalamin be supplemented  
in diabetic patients, particularly those  
receiving metformin treatment?
Vitamin B12 supplementation has been long consid-
ered safe due to its hydrophilicity and easy elimination 
from the body in case of an excess supply. This has been 
recently questioned, however, by the study findings 
published by Flores-Guerrero et al. [56] in the Journal 
of the American Medical Association. These authors 
showed an association between higher cobalamin level 
and higher mortality in the general population. Sur-
prisingly, this association became evident with plasma 
cobalamin levels within the reference range. This Dutch 
study followed more than 5000 adults for over 8 years. 
The identified association between cobalamin level and 
mortality was independent from age, gender, history 
of malignancies, renal and liver function parameters, 
concomitant type 2 diabetes, alcohol consumption, 
and smoking. Obesity, hypertension, dyslipidaemia, and 
hyperglycaemia were more common in patients with 
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plasma vitamin B12 levels in the upper quartile within 
the reference range. The exact significance of these cor-
relations and their mechanisms remain unknown and 
require further analyses. Based on these findings, the 
authors suggested avoiding vitamin B12 supplementa-
tion unless its deficiency is documented [56].
How to supplement vitamin B12?
In the past, the main approach to vitamin B12 
supplementation were regular (usually monthly) in-
tramuscular injections. Low popularity of oral intake 
was related to the belief that cobalamin absorption 
disturbances in various conditions lead to low bioavail-
ability of the oral form. However, even with the absence 
of active cobalamin transport mechanism, it partially 
crosses the intestinal mucosa by passive diffusion. If an 
appropriately large vitamin B12 dose is administered via 
this route, achieving an adequate increase in its serum 
level is possible [3]. Effective sublingual cobalamin 
administration techniques have also been developed. 
A vitamin B12 preparation administered sublingually 
as an aerosol has been recently introduced in Poland.
Until recently, the literature reports of effective 
sublingual supplementation were limited to small stud-
ies and case reports. Bensky et al. [57] investigated the 
efficacy of sublingual supplementation compared to 
intramuscular cobalamin administration in nearly 4300 
Israeli patients with vitamin B12 deficiency. Their study 
indicates that sublingual cobalamin administration ef-
fectively increased serum cobalamin level over a short 
time (the mean duration of follow-up was 7 months in 
the intramuscular cobalamin group and 9 months in the 
sublingual cobalamin group). The authors postulated 
superiority of this form of supplementation due to its 
convenience, lack of complications related to injec-
tions, and independence of the route of administra-
tion from the intrinsic factor and the gastrointestinal 
system status.
Sublingual administration results in cobalamin 
absorption directly to the bloodstream, avoiding poten-
tially adverse pH of the stomach and bypassing the en-
terohepatic circulation, which might reduce the amount 
of actually absorbed active substance of the oral prepa-
ration. This route is also beneficial with concomitant 
dysphagia. It seems, however, that with large vitamin 
B12 deficiencies requiring more rapid correction, the 
time-honoured intramuscular administration remains 
the preferred approach as its efficacy is confirmed by 
years of experience. In the study by Bensky et al. [57], 
the diagnostic and therapeutic reasoning underlying 
the choice of a particular route of supplementation in 
a given patient was not investigated. The intramuscular 
administration group was smaller and these patients 
had lower baseline serum cobalamin levels compared 
to the sublingual supplementation group. Thus, it is 
difficult to establish whether sublingual supplementa-
tion is superior to intramuscular injections [57]. Routes 
alternative to intramuscular injections are worth con-
sidering when an improvement of the patient quality 
of life is the primary consideration. They are also good 
alternative if intramuscular administration is contraindi-
cated, e.g., due to coagulopathy (including a iatrogenic 
one due to commonly used antithrombotic therapies).
summary  
The literature discussion on vitamin B12 supplemen-
tation in diabetic patients receiving metformin led to an 
increased interest in the importance of this vitamin in 
the management of diabetes and its complications. It 
seems that diabetic patients are at a potentially higher 
risk of cobalamin deficiency compared to individuals 
without diabetes. However, available laboratory tests 
do not allow discerning between blood levels of vita-
min B12 and its tissue content that drives the clinical 
manifestations of vitamin B12 deficiency. 
In addition to the natural disease course leading 
to micro- and macroangiopathic complications that 
might contribute to vitamin B12 deficiency, diabetic 
patients receive multi-drug therapy which may also 
aggravate this problem. In addition to metformin, most 
commonly used culprit medications include proton 
pump inhibitors, antibiotics, and non-steroidal anti-
inflammatory drugs.
These discussions of the recent decade have been 
summarized in the diabetic societies’ guidelines includ-
ing those published by ADA and the Diabetes Poland 
which have indicated the need for an early correction 
of vitamin B12 deficiency. 
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